Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Arista Networks Inc (ANET) vs Mesoblast Limited (MESO) Price & Performance

Arista Networks IncTrade
Mesoblast LimitedTrade

Price performance (Past 24H)

Key statistics

Arista Networks Inc vs Mesoblast Limited — how do they compare? Arista Networks Inc trades at $207.75 (market cap $249.53B), while Mesoblast Limited trades at $16.89 (market cap $2.21B). The key difference: Arista Networks Inc is far larger — about 112.9× Mesoblast Limited's market cap, and Arista Networks Inc is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals.

ANETMESO
Market Cap
$249.53B$2.21B
Sector
TechnologyTechnology
52-Week High
$197.85$20.96
52-Week Low
$116.13$12.88
Enterprise Value
$236.19B$2.21B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Arista Networks Inc

Arista Networks (ANET) trades at $191.52, up 1.51% with strong technical momentum and bullish moving average signals. The company demonstrates exceptional fundamentals with 38.4% net margins and consistent earnings beats, though valuation ratios remain elevated. Recent news highlights ANET's leadership in AI networking infrastructure with 40% revenue growth guidance for 2026, positioning it as a key beneficiary of hyperscaler capital expenditure cycles.

Outlook remains positive given robust AI-driven demand and strong analyst consensus, but premium valuation leaves little room for execution missteps. Key risks include competitive pressures and customer concentration with Meta and Microsoft comprising 42% of revenue. The stock offers growth exposure to AI infrastructure but requires monitoring of valuation sustainability.

Mesoblast Limited

MESO trades at $16.9, up 1.32% on the day, with a bullish technical signal from moving averages. The company reported Ryoncil net revenues of $36 million for the quarter ended June 30, 2026, and achieved its target of 300 patients in a Phase 3 trial for chronic low back pain. Despite strong revenue growth from its commercial launch, fundamentals show a net income margin of -144.33% and negative EBITDA of $80.06 million for 2025, reflecting significant losses amid expansion.

The outlook hinges on commercial execution and regulatory progress, with analyst consensus leaning buy (45% buy ratings). Key risks include high cash burn, dependence on pipeline success, and competitive pressures. Upside potential exists if revenue growth accelerates and losses narrow, but investors face volatility from clinical trial outcomes and funding needs.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Arista Networks Inc

Arista Networks is a software and hardware provider for the networking solutions sector. Operating as one business unit, software, switching, and router products are targeted for high-performance networking applications, while service revenue comes from technical support. Customer markets include data centers, enterprises, service providers, and campuses. The company is headquartered in Santa Clara, California, and generates most of its revenue in the Americas.

Read more on ANET

About Mesoblast Limited

Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.

Read more on MESO